Extended Data Fig. 4: Individual tumor growth curves and body weight curves for the experiments presented in main Fig. 6.
From: Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
a, Individual tumor growth curves for MC38 tumor-bearing mice (n = 6) treated intravenously with A12-VHHkappa-DM1 or A12-VHHkappa-DM4 at 5 mg/kg on day 7, 10,13, and 17 post-tumor injection as indicated by the arrows. b, Individual tumor growth curves for MC38 tumor-bearing mice (n = 6) treated intravenously with indicated VHH-DM4 conjugates at 5 mg/kg on day 7, 10,13, and 17 post-tumor injection as indicated by the arrows. c, Individual tumor growth curves (upper panels) and body weight curves (lower panel, data represent mean ± SD) for B16-F10 tumor-bearing mice (n = 5) treated intravenously with indicated VHH-DM4 conjugates at 5 mg/kg on day 3, 6, 9, and 13 post-tumor injection as indicated by the arrows.
